Hyperplastic polyposis syndrome: Endoscopic treatment and surveillance.

No registrations found.

Ethical review	Not applicable
Status	Recruiting
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON27090

Source
Nationaal Trial Register

Brief title
HPSB

Health condition

hyperplastic polyposis CRC serrated adenoma HPSB colorectal carcinoma HPS

Sponsors and support

Primary sponsor: Academic Medical Centre (AMC)
Source(s) of monetary or material Support: Dutch Cancer Society

Intervention

Outcome measures

Primary outcome

To prospectively assess the efficacy, feasibility and safety of a systemised endoscopic surveillance protocol in large multicentre HPS cohort.

Secondary outcome

The incidence of complications: The amount of polypectomies and the rate of protcol deviations and conversions to surgical resection will be assessed.

Study description

Background summary

Hyperplastic polyposis syndrome (HPS) is characterized by the presence of multiple colorectal serrated polyps and is associated with an increased colorectal cancer (CRC) risk. The prevalance of HPS is estimated to be 1:3000 which makes HPS more common than other polyposis syndromes such as FAP. Due to the risk of malignant polyp transformation, HPS patients undergo endscopic surveillance with removal of polyps or a surgical colonic resection. However, no uniform and adequately substantiated endoscopic management protcol exists regarding polyp removal and surveillance intervals.

Aim:

To prospectively assess the efficacy, feasibility and safety of a systemised endoscopic surveillance protocol in large multicentre HPS cohort.

Study objective

To prospectively assess the efficacy, feasibility and safety of a systemised endoscopic surveillance protocol in large multicentre HPS cohort.

Study design

3 years.

Intervention

Data are collected in prospective manner from patients during a routine annual endoscopies with removal of all polyps < 3 mm.

Contacts

Public
Meibergdreef 9
Y. Hazewinkel

Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5662806
Scientific
Meibergdreef 9
Y. Hazewinkel
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5662806

Eligibility criteria

Inclusion criteria

HPS patients defined as:

> 5 HPs/SSA proximal to the sigmoid, of which 2 > 10 mm in diameter, or more than 20 HPs/SSAs distributed throughout the colon.

Exclusion criteria

Carriers of a germline mutation in the MutYH or APC gene and individuals who have undergone a total colonic resection.

Study design

Design

Study type:	Observational non invasive
Intervention model:	Factorial
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	01-06-2010
Enrollment:	125
Type:	Anticipated

Ethics review

Not applicable
Application type: Not applicable

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL2629
NTR-old	NTR2757
Other	METC AMC : 10.17.2005
ISRCTN	ISRCTN wordt niet meer aangevraagd.

Study results

Summary results
N/A